Cytokine Production by Tumor Bioptate at Different Pathological Prognostic Stages in Breast Cancer

Autenshlyus, A. I.; Studenikina, A. A.; Вараксин, Н. А.; Lyakhovich, V. V.

doi:10.1134/s1607672921020010

Cited by 7 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrarily, literature demonstrated IL-18 as a pro-oncogenic cytokine (Ref. 75) where its expression in BC led to enhanced invasion, metastasis (Refs 76, 77, 78, 79, 80, 81), migration (Refs 76, 82), proliferation (Ref. 83), angiogenesis (Ref.…”

Section: What Are Inflammasomes?mentioning

confidence: 99%

Inflammasomes in breast cancer: the ignition spark of progression and resistance?

Elgohary

Tayebi

2023

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

Inflammation and immune evasion are major key players in breast cancer (BC) progression. Recently, the FDA approved the use of anti-programmed death-ligand 1 antibody (anti-PD-L1) and phosphoinositide 3-kinase (PI3K) inhibitors against aggressive BC. Despite the paradigm shift in BC treatments, patients still suffer from resistance, recurrence and serious immune-related adverse events. These obstacles require unravelling of the hidden molecular contributors for such therapy failure hence yielding therapeutics that are at least as efficient yet safer. Inflammasome pathway is activated when the pattern recognition receptor senses danger signals (danger-associated molecular patterns) from damagedRdying cells or pathogen-associated molecular patterns found in microbes, leading to secretion of the active pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18). It has been shown throughout numerous studies that inflammasome pathway enhanced invasion, metastasis, provoked BC progression and therapy resistance. Additionally, inflammasomes upregulated the proliferative index ki67 and enhanced PD-L1 expression leading to immunotherapy resistance. IL-1β contributed to significant decrease in oestrogen receptor levels and promoted BC chemo-resistance. High levels of IL-18 in sera of BC patients were associated with worst prognosis. Stimulation of purinergic receptors and modulation of adipokines in obese subjects activated inflammasomes that evoked radiotherapy resistance and BC progression. The micro RNA miR-223-3p attenuated the inflammasome over-expression leading to lowered tumour volume and lessened angiogenesis in BC. This review sheds the light on the molecular pathways of inflammasomes and their impacts in distinct BC subtypes. In addition, it highlights novel strategies in treatment and prevention of BC.

show abstract

Section: What Are Inflammasomes?mentioning

confidence: 99%

Inflammasomes in breast cancer: the ignition spark of progression and resistance?

Elgohary

Tayebi

2023

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

show abstract

“…Considered as the hormones of the immune system, many cytokines, such as TNF-α, IL-1β, IL-2, IL-6, IL-12 and IL-15, have already been utilized in cancer immunotherapies either to enhance growth inhibitory effects or suppress tumor-promoting actions [6,7]. While a histology-independent uniform cytokine cascade was noticed in different types of cancers, unique cytokine expression patterns are also being identified in specific cancer types [8,9], which may be developed as potential diagnostic biomarkers or therapeutic targets [6,10,11].…”

Section: Introductionmentioning

confidence: 99%

Cytokine expression patterns: A single-cell RNA sequencing and machine learning based roadmap for cancer classification

Ren,

Liu

et al. 2024

Computational Biology and Chemistry

View full text Add to dashboard Cite

“…Considered as the hormones of the immune system, many cytokines, such as TNF- α , IL-1 β , IL-2, IL-6, IL-12 and IL-15, have already been utilized in cancer immunotherapies either to enhance growth inhibitory effects or suppress tumor-promoting actions [6], [7]. While a histology-independent uniform cytokine cascade is noticed in different types of cancers, unique cytokine expression patterns are also being identified in specific cancer types [8], [9], which may be developed as potential diagnostic biomarkers or therapeutic targets [6], [10], [11].…”

Section: Introductionmentioning

confidence: 99%

Cytokine expression patterns: A single-cell RNA sequencing and machine learning based roadmap for cancer classification

Ren

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Cytokines are small protein molecules exhibit potent immunoregulatory properties, which are known as the essential components of tumor immune microenvironment (TIME). While some cytokines are known to be universally upregulated in TIME, the unique cytokine expression patterns have not been fully resolved in specific types of cancers. In this study, single-cell RNA sequencing (scRNA-seq) data was collected from multiple public repositories, filtered and processed to visualize the cytokine expressions in different immune cells in TIME. The TIME dataset including 39 cancer types was constructed based on the 695 processed immune cell-containing samples. With a random forest model, unique cytokine expression patterns were identified for various cancer categories with high accuracy of nearly 80%. The results will not only boosting the understanding of the cancer type-specific immune modulations in TIME, but also server as an crucial reference for future diagnostic and therapeutic researches in cancer immunity.

show abstract

Cytokine Production by Tumor Bioptate at Different Pathological Prognostic Stages in Breast Cancer

Cited by 7 publications

References 11 publications

Inflammasomes in breast cancer: the ignition spark of progression and resistance?

Inflammasomes in breast cancer: the ignition spark of progression and resistance?

Cytokine expression patterns: A single-cell RNA sequencing and machine learning based roadmap for cancer classification

Cytokine expression patterns: A single-cell RNA sequencing and machine learning based roadmap for cancer classification

Contact Info

Product

Resources

About